AstraZeneca formed a partnership with Daiichi Sankyo regarding Enhertu, and also established a profit-sharing deal with Merck for Lynparza.
3 reports, 1 independent
Updated Aug 15
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca formed a partnership with Daiichi Sankyo regarding Enhertu, and also established a profit-sharing deal with Merck for Lynparza.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The European Union granted approval for Enhertu, a drug co-developed by AstraZeneca and Daiichi Sankyo.Sub-event
AstraZeneca partnered with Daiichi Sankyo on Enhertu and secured a profit-sharing deal with Merck for Lynparza.1 source
Keep exploring
The entities involved
-
Daiichi Sankyo (United Kingdom)
company in Chalfont Saint Peter, United Kingdom
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
-
Merck
public company in Indonesia
Related events
- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- Chinese pharmaceutical companies are investing heavily in novel technologies while AstraZeneca confirms its Cambridge headquarters and CEO.
- AstraZeneca acquired Fusion Pharmaceuticals for approximately US$2 billion in 2024.
- Kailera Therapeutics and Hengrui announced a multi-billion-dollar partnership, while Merck seeks pipeline assets to offset revenue decline.
Coverage
Newest first; wire copies grouped- ZacksAstraZeneca Rides Oncology Momentum With Blockbuster and New Drugs AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 43% of AstraZeneca‘s total
- ZacksHow Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings? Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is on diabetes an
- Unknown outlet